Evidence map›Paper›PMID 39535309›Full record

ArticleEuropean journal of haematology2025

Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter Analysis.

T Richardson, G Kobbe, R Fenk, T Schroeder, M Crysandt, C Neuerburg, Tobias A W Holderried, D Schütte, P Gödel, M Hallek and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

T RichardsonDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Köln, Germany.ORCID https://orcid.org/0009-0006-3588-6376
G KobbeDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Germany.
R FenkDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Germany.
T SchroederUniversity Duisburg-Essen, University Hospital Essen, Stem Cell Transplant, Germany.
M CrysandtUniversity Hospital Aachen, Medical Clinic IV, Stem Cell Transplantation, Aachen, Germany.
C NeuerburgDepartment of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Tobias A W HolderriedDepartment of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany.
D SchütteDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Köln, Germany.
P GödelDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Köln, Germany.
M HallekDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Köln, Germany.
C ScheidDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Köln, Germany.
U HoltickDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Köln, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing list of therapies available for patients with multiple myeloma (MM) results in deep response rates, but eventually almost all patients relapse. Allogeneic hematopoietic cell transplantation (allo-SCT) is a familiar approach for MM, but responses are often short and side effects burdensome. Simultaneously, allo-SCT provides a unique platform on which novel immune therapies can be employed to improve clinical outcomes. Our work describes the characteristics and outcomes of 128 refractory myeloma patients who underwent allo-SCT at five German centers between 2010 and 2021. The median number of therapies before the transplant was 6. With a median follow-up of 6, 4 years, the median progression-free survival and overall survival were 7 and 19 months, respectively. NRM was 28% after 6 years. OS and PFS were 61% and 45% at 1 year, 49% and 34% at 2 years, and 38% and 25% at 6 years. Achieving a CR before transplant was the single most significant variable before transplant. Allo-SCT yet remains an option for fit patient's refractory to all other treatments available. It is potentially curative for a subset of patients. Finding the characteristics of patients with durable remissions is key to sparing unnecessary toxicity for those unlikely to benefit.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTransplantation ConditioningTransplantation, HomologousTreatment Outcomeallogeneic hematopoietic stem cell transplantationlong‐term outcomemultiple myeloma

Identifiers

PMID39535309
PMCPMC11798762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.